HONG KONG – GI Innovation Inc., a microbiome combination drug developer based in Seoul, South Korea, has recently issued fully paid convertible preferred stock (CPS) worth KRW37.5 billion (US$31 million) for a series B investment.
The Asia Pacific region (APAC) is vast and awash with varied economies, languages, governments and ambitions. That's the backdrop for its dramatic underperformance compared to the West's pharmaceutical innovations. Yet plenty of opportunities exist, along with a healthy dose of uncertainty, according to the first Pharmaceutical Innovation in the APAC region report, published by Clarivate Analytics plc.
PERTH, Australia – There is pervasive use of artificial intelligence and machine learning (AI/ML) across the health care industry in Australia, and excitement is building on the opportunities it offers to technologies and ultimately to patients, Ausbiotech CEO Lorraine Chiroiu told BioWorld Asia.